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ORIGINAL ARTICLE
Poor pregnancy outcome in women with type 1 diabetes is predicted by
elevated HbA1c and spikes of high glucose values in the third trimester
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and Elisabeth R. Mathiesen1
1Departments of Endocrinology and Obstetrics, Center for Pregnant Women with Diabetes, Rigshospitalet, Faculty of Health Sciences, University of
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Abstract
Objective: To analyse data from a randomised, controlled study of prandial insulin aspart versus
human insulin, both with NPH insulin, in pregnant women with type 1 diabetes for potential
factors predicting poor pregnancy outcomes.
Research design/method: Post hoc analysis including 91 subjects randomised prior to pregnancy
with known outcome in early pregnancy and 259 subjects randomised prior to pregnancy/
during pregnancy of510 weeks’ gestation with known late-pregnancy outcomes. Poor early-
pregnancy outcomes included fetal loss522 gestational weeks and/or congenital malformation
(n¼ 18). Poor late-pregnancy outcomes included: composite endpoint including pre-eclampsia,
preterm delivery and perinatal death (n¼ 78); preterm delivery (n¼ 63); and excessive fetal
growth (n¼ 88).
Results: 18 patients experienced a malformed/lost fetus in early pregnancy – none preceded
by severe hypoglycaemia. Albuminuria in early pregnancy was a significant predictor of poor
late-pregnancy outcome (composite endpoint; p¼ 0.012). In the third trimester, elevated
HbA1c, 1 plasma glucose (PG) measurement411mmol/L (198mg/dL) and %PG values outside
3.9–7.0mmol/L (70–126mg/dL) were significant predictors of poor late-pregnancy outcomes
(all p50.05).
Conclusions: Elevated HbA1c, high glucose spikes and out-of-range %PG in the third trimester,
and albuminuria in early pregnancy, are associated with poor late-pregnancy outcomes.
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Introduction
It has long been recognised that pregnant women with type 1
diabetes experience higher rates of poor maternal, fetal and
perinatal outcomes compared with normal pregnancies;
indeed, large prospective studies have reported rates of
congenital malformation and mortality around three-times
higher than those observed in nondiabetic pregnancy [1,2].
Poor outcomes in type 1 diabetes pregnancy, such as preterm
delivery or large for gestational age (LGA) babies, have been
shown to be associated with hyperglycaemia and elevated
HbA1c [3–5]. In addition, the risk of developing pre-
eclampsia is significantly higher in pregnant women with
type 1 diabetes who had poor glycaemic control than in those
with optimal HbA1c control [6]. Even in pregnant women
without diabetes, maternal glucose levels have been shown to
be continuously associated with increased birth weight and
other perinatal complications [7].
Consequently, the aim of treatment in pregnant women
with type 1 diabetes is to achieve strict glycaemic control,
preferably from before conception, and to maintain low
HbA1c levels throughout pregnancy [8]. However, there are
conflicting data concerning the trimester in which it is most
important to intensify glycaemic control [5,9–12]. One study
found that glycaemic control at conception and in the first
trimester were the most important for reducing macrosomia
[10], while a more recent study demonstrated that only
increased second-trimester glucose levels were associated
with LGA babies [5]. Two other studies reported that neonatal
morbidity was most closely associated with glycaemic control
in the second and third trimesters [9,11]. It has also been
shown in animal models that severe hypoglycaemia can result
in malformation [13], although human data in this area are
sparse.
Prospective studies investigating insulin treatment in
pregnant women with type 1 diabetes are limited. In this
post hoc analysis, potential factors affecting poor outcomes in
early and late pregnancy were examined. The data were
generated from a randomised, controlled study in pregnant
women with type 1 diabetes (n¼ 322) investigating the safety
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and efficacy of a rapid-acting insulin analogue (prandial
insulin aspart) versus prandial human insulin, both in com-
bination with insulin NPH [14,15]. The trial included both
women who were planning pregnancy and those who were
pregnant.
Research design and methods
The trial included 322 women with type 1 diabetes who
were planning pregnancy or were already pregnant, and has
been described previously [14,15]. Metabolic control was
measured at a randomisation/first-pregnancy assessment; at
clinic visits at the end of the first, second and third
trimesters (at approximately 12, 24 and 36 gestational weeks
[GWs], respectively); and at delivery and follow-up 6 weeks
postpartum [14,15]. Laboratory analyses (HbA1c, haematol-
ogy, biochemistry, and urinalysis) were performed by MDS
Pharma Services Central Lab (Hamburg, Germany). HbA1c
was analysed using a National Glycohemoglobin
Standardization program – certified method (Diabetes
Control and Complications Trial standard) [14,15].
Poor outcomes in early and late pregnancy were cate-
gorised by their randomisation status. The analysis for
congenital malformations (minor or major) and fetal loss in
early pregnancy was confined to subjects who were
randomised before pregnancy and with known outcome
(n¼ 91). Those pregnant at randomisation were excluded
from this analysis, as these subjects were not observed until
GW 10, and thus fetal losses up to GW 10 may not have been
recorded. The poor outcome in early pregnancy data set was,
therefore, defined as all pregnant subjects randomised prior to
pregnancy with either fetal loss before 22 completed GWs
(n¼ 17) or known outcome after GW 22 (n¼ 74; Online
Supplemental Figure 1). The composite endpoint for poor
outcome in early pregnancy included fetal loss before GW 22
and/or congenital malformations.
The poor outcome in the late pregnancy analysis data set
comprised subjects randomised both before pregnancy and in
early pregnancy, and included 259 subjects with a successful
pregnancy beyond GW 22 while excluding subjects with
unknown outcome, fetal loss before GW 22 weeks and/or
congenital malformations (n¼ 63; Online Supplemental
Figure 1).
Three endpoints were examined for poor outcome in late
pregnancy: 1) a composite endpoint including pre-eclampsia,
preterm delivery (537 weeks) and perinatal death (n¼ 78);
2) preterm delivery (n¼ 63); and 3) excessive fetal growth
(LGA/macrosomia; n¼ 88). LGA was defined as birth weight
490th percentile according to local growth charts and
macrosomia as birth weight44000 g.
Factors investigated as predictors of poor outcome in early
pregnancy included: HbA1c46% (yes, no; measured at the
first trimester visit); plasma glucose (PG)411 mmol/L
(198 mg/dL; yes, no; measured from an 8-point PG profile
performed within 1 week prior to the first-trimester visit);
albuminuria at baseline (yes, no); retinopathy at baseline (yes,
no); and major hypoglycaemia preceding the outcome. Major
hypoglycaemia was defined as an episode where the subject
was unable to treat herself and which had at least one of the
following characteristics: PG53.1 mmol/L (56 mg/dL) and/or
reversal of symptoms after either food intake or glucagon/
intravenous (i.v.) glucose administration.
Possible predictors of poor outcome in late pregnancy
included: HbA1c at third-trimester visit (continuous variable);
PG411 mmol/L (198 mg/dL; yes, no); and percentage of PG
values outside the reference range (i.e. values below
3.9 mmol/L [72 mg/dL] or above 7.0 mmol/L [126 mg/dL];
all PG values were from an 8-point PG profile performed
within 1 week prior to the third-trimester visit); insulin
analogue as previous therapy (yes, no); including either
analogues prescribed prior to trial or randomised insulin
aspart; blood pressure; albuminuria (yes, no); and retinopathy
(yes, no) at baseline for subjects pregnant at randomisation
and at start of pregnancy visit for subjects not pregnant at
randomisation. Albuminuria was defined as one or more
measurements of albumin in a spot urine sample430 mg/L.
Retinopathy was defined as clinically significant abnormal
funduscopy as determined by country-specific practice.
For predictors of poor outcome in early pregnancy, odds
ratios and 95% confidence intervals were calculated using the
continuity correction with corresponding Chi-square tests.
Multivariate analysis was not performed due to the limited
number of cases.
Predictors of poor outcome in late pregnancy were
analysed using multiple logistic regression. The model
included adjustment for BMI (kg/m2), age (years), smoker
(yes, no), duration of diabetes and parity (0 or 1
pregnancies) as basis [16,17]. In this model, possible
individual predictors were entered one at a time. Hereafter,
all predictor variables with p50.10 in each of the previous
models, in addition to predictors in base model, were included
in a multivariate logistic regression model. Of the plasma
glucose variables, only PG411 mmol/L (4198 mg/dL) was
included in the multivariate model, as both this variable and
the percentage of PG readings outside the reference range
(3.9–7.0 mmol/L [72–126 mg/dL]) were assumed to be highly
correlated. Statistical significance for predictors in the full
model was determined based on a 5% significance level.
Results
Eighteen women had a malformed fetus (n¼ 1), fetal loss
(n¼ 15) or both (n¼ 2). No significant predictors were found
for this poor outcome in early pregnancy (Online
Supplemental Table 1). For the pregnancies resulting in
congenital malformation or early fetal loss, there was no
documentation of major hypoglycaemia in the first trimester.
The composite endpoint of poor outcome in late pregnancy
included preterm delivery (n¼ 53), pre-eclampsia (n¼ 12),
both preterm delivery and pre-eclampsia (n¼ 10), stillbirth
(n¼ 2) and death within 1 week postnatally (n¼ 1).
In the initial analysis of the composite endpoint, HbA1c, at
least one PG measurement411 mmol/L (4198 mg/dL), %PG
values outside of the reference range in the third trimester, and
presence of albuminuria at baseline were significant predictors
of poor outcome in late pregnancy (Table 1). When all
significant predictors from the first analysis were entered
simultaneously into the full model, only albuminuria at
baseline remained statistically significant. Patients who had a
poor outcome as defined by the composite endpoint in late
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pregnancy had a higher mean HbA1c during pregnancy (based
on a total of three measurements taken at the end of each
trimester) compared with those who did not have a poor
outcome (not analysed statistically; Online Supplemental
Figure 2A).
%PG values outside of the reference range, at least one
measurement of PG411 mmol/L (4198 mg/dL) and HbA1c in
the third trimester, and albuminuria at baseline were also
significant predictors of preterm delivery in the initial
analyses (Table 2).
The odds ratio of 2.00 for at least one measurement of
PG411 mmol/L (4198 mg/dL) indicates that these patients
are twice as likely to experience preterm delivery compared to
patients with all PG measurements 511 mmol/L
(5198 mg/dL). Likewise, a 1%-point increase in HbA1c
almost doubled the odds of preterm delivery (OR 1.75).
Table 1. Predictors of poor outcome in late pregnancy given a successful outcome in early pregnancy.
Predictor
Successful outcome
(n¼ 181)
Poor outcome
(n¼ 78)
Odds ratio
(CI), model 1
p Value,
model 1
p Value,
model 2
Base model
BMI (mean, SD), kg/m2 24.7 (3.9) 24.7 (3.5) 0.99 (0.92,1.07) 0.765 0.707
Age (mean, SD), years 28.9 (4.7) 29.1 (4.8) 1.01 (0.95,1.08) 0.791 0.842
Smoker, yes 13 (7%) 8 (10%) 1.66 (0.64,4.30) 0.297 0.724
Duration of diabetes (mean, SD), years 11.8 (6.9) 12.5 (8.5) 1.01 (0.97,1.06) 0.525 0.830
Parity
0 84 (46%) 42 (54%) 0.72 (0.41,1.24) 0.236 0.252
1 or more 97 (54%) 36 (46%)
Predictors
Systolic BP (mean, SD), mmHg 114.0 (10.0) 114.0 (12.0) 1.00 (0.98,1.03) 0.720 NA
Diastolic BP (mean, SD), mmHg 70.2 (8.7) 69.8 (8.4) 1.00 (0.97,1.03) 0.884 NA
Insulin analogue treatment, yes 97 (54%) 35 (45%) 0.69 (0.40,1.19) 0.184 NA
Presence of albuminuria, yes 6 (3%) 9 (12%) 4.11 (1.36,12.43) 0.012 0.007
Presence of retinopathy, yes 18 (10%) 8 (10%) 0.99 (0.40,2.47) 0.990 NA
PG411 mmol/L [4198 mg/dL], yes 34 (19%) 26 (34%) 2.12 (1.14,3.92) 0.017 0.092
PG outside range (mean, SD), % 44.5 (23) 51.6 (23) 1.01 (1.00,1.02) 0.045 NA
HbA1c (mean, SD), % 6.0 (0.6) 6.2 (0.7) 1.68 (1.08,2.61) 0.022 0.058
Statistics are mean (standard deviation [SD]) for continuous predictors and frequency (percentage) for categorical predictors. All values apart from
plasma glucose (PG)411 mmol/L (4198 mg/dL), %PG in range and HbA1c (%) are taken from baseline or screening for subjects pregnant at
randomisation and from start of pregnancy visit for subjects not pregnant at randomisation.
%PG outside of range indicates those PG values falling below 3.9 mmol/L (70 mg/dL) or above 7.0 mmol/L (126 mg/dL). PG and HbA1c values were
taken from the third-trimester study visit. If the third-trimester study visit value was missing, the second-trimester study visit value was used.
p Value model 1: logistic regression adjusting for BMI, age, smoking, duration of diabetes and parity.
p Value model 2: model 1 þ predictors with a p value from model 1510%.
BP, blood pressure; CI, confidence interval; NA, not included in model.
Table 2. Predictors of preterm delivery in late pregnancy.
Predictor
Delivery at term
(n¼ 194)
Preterm delivery
(n¼ 63)
Odds ratio
(CI) model 1
p Value
model 1
p Value
model 2
Base model
BMI (mean, SD), kg/m2 24.7 (3.8) 24.7 (3.7) 0.99 (0.91,1.07) 0.748 0.774
Age (mean, SD), years 28.8 (4.6) 29.3 (4.9) 1.02 (0.95,1.09) 0.620 0.670
Smoker, yes 13 (7%) 8 (13%) 2.35 (0.89,6.18) 0.083 0.328
Duration of diabetes (mean, SD), years 11.7 (6.9) 12.8 (8.8) 1.02 (0.98,1.07) 0.377 0.646
Parity
0 90 (46%) 34 (54%) 0.69 (0.38,1.24) 0.215 0.284
1 or more 104 (54%) 29 (46%)
Predictors
Systolic BP (mean, SD), mmHg 114.0 (10.0) 113.0 (12.0) 0.99 (0.96,1.02) 0.574 NA
Diastolic BP (mean, SD), mmHg 70.3 (8.6) 69.2 (8.5) 0.99 (0.95,1.02) 0.529 NA
Insulin analogue, yes 103 (53%) 28 (44%) 0.70 (0.39,1.25) 0.224 NA
Presence of albuminuria, yes 8 (4%) 7 (11%) 2.98 (0.99,8.94) 0.051 0.036
Presence of retinopathy, yes 19 (10%) 7 (11%) 1.08 (0.42,2.82) 0.868 NA
PG411 mmol/L [4198 mg/dL], yes 38 (20%) 21 (34%) 2.00 (1.04,3.84) 0.038 0.204
%PG outside range (mean, SD) 44.4 (23) 53.4 (23) 1.02 (1.00,1.03) 0.024 NA
HbA1c (mean, SD), % 6.0 (0.6) 6.3 (0.7) 1.75 (1.08,2.82) 0.023 0.045
Statistics are mean (standard deviation [SD]) for continuous predictors and frequency (percentage) for categorical predictors. All values apart from
plasma glucose (PG)411 mmol/L (4198 mg/dL), %PG in range and HbA1c (%) are taken from baseline or screening for subjects pregnant at
randomisation and from start of pregnancy visit for subjects not pregnant at randomisation.
%PG outside of range indicates those PG values falling below 3.9 mmol/L (70 mg/dL) or above 7.0 mmol/L (126 mg/dL). HbA1c values were taken from
the third trimester study visit. If the third-trimester study visit value was missing, the second-trimester study visit value was used.
p Value model 1: logistic regression adjusting for BMI, age, smoking, duration of diabetes and parity.
p Value model 2: model 1 þ predictors with a p value from model 1510%.
CI, confidence interval; NA, not included in model.
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When all significant predictors from the first models were
analysed together, only HbA1c in the third trimester and
albuminuria at baseline remained statistically significant.
At least one measurement of PG411 mmol/L
(4198 mg/dL), %PG values outside of range and HbA1c were
also all significantly associated with LGA/macrosomia (Table
3), and both HbA1c and at least one measurement of
PG411 mmol/L (4198 mg/dL) remained significant pre-
dictors when analysed in the full model. Again, patients
experiencing preterm delivery or LGA/macrosomia appeared
to have a higher mean HbA1c over time compared with patients
who delivered at term or had normal-weight babies (not
analysed statistically; Online Supplemental Figure 2B and C).
The percentage of patients experiencing LGA/macrosomia
increased with increasing third-trimester HbA1c when
expressed categorically: HbA1c55.5%, 19% of patients
experiencing LGA/macrosomia; HbA1c 5.5–5.9%, 26%;
HbA1c 6–6.4%, 35%; HbA1c46.4%, 52%. Other potential
predictors (previous use of insulin analogues, blood pressure,
retinopathy in early pregnancy) did not predict any of the three
outcomes (p40.10).
Discussion
These results suggest that both elevated HbA1c and spikes of
high glucose levels have a negative impact on pregnancy
outcomes in women with type 1 diabetes, especially on excess
growth of the fetus. This emphasises the importance of
keeping HbA1c within the normal range throughout preg-
nancy, and not only during a particular trimester. Our findings
therefore support the recommendation to also strive for
optimal glycaemic control in late pregnancy in women with
type 1 diabetes.
The literature on early fetal loss in type 1 diabetic
pregnancy is very limited despite considerable interest,
especially from patients. None of the cases of malformation
or fetal death in early pregnancy were preceded by an episode
of severe hypoglycaemia. The 12 patients who experienced a
major hypoglycaemic episode in the first trimester all had a
successful outcome in early pregnancy; therefore, a link
between major hypoglycaemia and poor pregnancy outcome
is not supported by this study.
Poor outcomes in late pregnancy were most strongly
predicted by albuminuria and by measures of glucose control.
It is well recognised that the prevalence of adverse pregnancy
outcome is higher among women with albuminuria, mainly
due to pre-eclampsia [18]. In terms of glucose measures,
HbA1c and PG, in particular any PG measurement411 mmol/
L (4198 mg/dL), were significant predictors of poor outcome
in late pregnancy. This suggests that, not only should HbA1c
be maintained at a low level throughout pregnancy, but also
day-to-day glucose profiles should be kept stable, and high
peaks of glucose should be avoided. Elevated HbA1c and PG
are associated with a poor outcome in late pregnancy. In this
respect, these data support the already well-recognised
association of hyperglycaemia with increased maternal, fetal
and perinatal morbidity. Our data indicate, however, that
patients with successful outcomes for the composite endpoint,
preterm delivery and LGA/macrosomia have lower HbA1c
levels than patients with poor outcomes, and this is evident
throughout pregnancy.
There is potential for multicollinearity when considering a
large number of predictors. HbA1c is closely associated with
mean and high PG and, therefore, it is not remarkable when
considering poor late-pregnancy outcome or preterm delivery
that PG is no longer significant in the full model, where both
Table 3. Predictors of LGA/macrosomia in late pregnancy.
Predictor
No
(n¼ 169)
Yes
(n¼ 88)
Odds ratio
(CI) model 1
p Value
model 1
p Value
model 2
Base model
BMI (mean, SD), kg/m2 24.8 (3.7) 24.5 (3.8) 0.98 (0.91,1.05) 0.587 0.615
Age (mean, SD), years 28.9 (4.7) 28.9 (4.6) 0.99 (0.93,1.05) 0.687 0.496
Smoker, yes 16 (9%) 5 (6%) 0.55 (0.19,1.60) 0.274 0.392
Duration of diabetes (mean, SD), years 12.1 (7.1) 11.8 (8.1) 1.00 (0.96,1.04) 0.993 0.756
Parity
0 87 (51%) 37 (42%) 1.55 (0.90,2.65) 0.113 0.099
1 or more 82 (49%) 51 (58%)
Predictors
Systolic BP (mean, SD), mmHg 114.0 (10.0) 113.0 (12.0) 0.99 (0.97,1.02) 0.530 NA
Diastolic BP (mean, SD), mmHg 70.4 (8.7) 69.3 (8.2) 0.98 (0.95,1.01) 0.282 NA
Insulin analogue, yes 91 (54%) 40 (45%) 0.72 (0.42,1.21) 0.216 NA
Presence of albuminuria, yes 12 (7%) 3 (3%) 0.48 (0.13,1.80) 0.278 NA
Presence of retinopathy, yes 19 (11%) 7 (8%) 0.63 (0.25,1.62) 0.341 NA
PG411 mmol/L [4198 mg/dL], yes 29 (17%) 30 (35%) 2.72 (1.47,5.06) 0.002 0.027
%PG outside range (mean, SD) 43.9 (23) 51.9 (23) 1.02 (1.01,1.03) 0.004 NA
HbA1c (mean, SD), % 6.0 (0.6) 6.3 (0.6) 2.73 (1.72,4.33) 0.000 0.001
Statistics are mean (standard deviation [SD]) for continuous predictors and frequency (percentage) for categorical predictors. All values apart from
plasma glucose (PG)411 mmol/L (4198 mg/dL), %PG in range and HbA1c (%) are taken from baseline or screening for subjects pregnant at
randomisation and from start of pregnancy visit for subjects not pregnant at randomisation.
%PG outside of range indicates those plasma glucose values falling below 3.9 mmol/L (70 mg/dL) or above 7.0 mmol/L (126 mg/dL). PG and HbA1c
values were taken from the third-trimester study visit. If the third-trimester study visit value was missing, the second-trimester study visit value was
used.
p Value model 1: logistic regression adjusting for BMI, age, smoking, duration of diabetes and parity.
p Value model 2: model 1þ predictors with a p value from model 1510%.
CI, confidence interval; NA, not included in model.
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variables are entered simultaneously. However, the full
analysis establishes that HbA1c on its own explains part
of the variance in the prediction of preterm delivery and
LGA/macrosomia.
To our knowledge, this is one of the first studies seeking to
establish the effects of spikes of high glucose values on
pregnancy outcome [19]. Pregnant women and their diabetes
caregivers may fear such glucose excursions; however, the
occurrence of glucose spikes is not easily detected as these
may not always be reflected in patients’ HbA1c values.
Additionally, data from two randomised trials have suggested
that effectively managing postprandial glucose levels is more
likely to be associated with a successful pregnancy outcome
than controlling fasting glucose levels [20,21], highlighting
the importance of recognising and treating high glucose
spikes. In the present study, spikes of high glucose values
(PG411 mmol/L [4198 mg/dL]) were a stronger predictor for
LGA/macrosomia than for preterm delivery. This is supported
by the fact that LGA/macrosomia is directly influenced by
glucose levels, whereas preterm delivery is also influenced by
many other factors.
Examination of LGA/macrosomia by category of HbA1c
indicates that high HbA1c levels are associated with a poor
outcome, and the estimated odds ratios demonstrate that, for
any increase in HbA1c or PG, the risk of experiencing preterm
delivery or LGA/macrosomia increases. On the contrary,
HbA1c55.5% is associated with a relatively low incidence of
LGA/macrosomia. These findings are in line with a recent
study [22], which demonstrated that increased third-trimester
HbA1c predicted higher birth weight. Macrosomia is asso-
ciated with an increased rate of Caesarean section, shoulder
dystocia, neonatal hypoglycemia and longer hospitalisation
[23]. In addition to this, children born to mothers with type 1
diabetes may have an increased risk of being overweight and
of developing metabolic syndrome and/or type 2 diabetes in
early adulthood [24,25].
Therefore, the results from this post hoc analysis confirm
that glucose levels and HbA1c should be carefully controlled
throughout the entire pregnancy to ensure a successful
outcome in patients with type 1 diabetes.
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